Key Takeaways
- Strategic reset masks underlying momentum: Reported revenue grew 7% YoY, but excluding the deliberate South Africa rationalization, growth was 10% in Q3 and 14% over nine months. The trade-off was intentional: sacrificing top-line for a 530 bps YoY gross margin expansion.
- Domestic business is the engine: India revenue grew 14% YoY to INR462 crore, driven by chronic therapies and an acute recovery. The covered market grew 200 bps faster than IPM, and the CVM portfolio within it grew at 16%.
- Ophthalmology entry is a material new vector: The Novartis deal instantly makes J.B. a top-4 ophthalmology player in the covered market, with five #1 brands and four more in the top 3. Management declined to quantify the margin impact, calling it too early.
- Margin guidance held, with an upgrade path: EBITDA margin guidance stays at 25–27%, but management flagged that as chronic and CDMO contributions become substantial, that range will be revised upward.
- What to watch next quarter: Details on the ophthalmology portfolio’s economics after the first 100 days, whether the South Africa drag ends on schedule by Q1, and any revision to the 25–27% margin band.
Domestic Business: Chronic Strength, Acute Recovery
- Chronic franchises driving mix shift: The Cilacar, Razel, and Nicardia franchises, plus improving Azmarda margins, are the product families lifting gross margins. The domestic business has transitioned from stable, low-growth segments to progressive, higher-value chronic therapies over three years.
- Acute business recovering: The acute portfolio contributed to the 14% domestic growth, indicating a broad-based recovery beyond just the chronic book.
- Sporlac franchise scaling: The probiotic portfolio jumped 30 ranks YoY to #331 and now stands at INR121 crore in total franchise units, with new launches under the same brand umbrella performing well.
- Domestic growth ambition: J.B. targets 200–300 bps above IPM growth; with IPM expected at ~10%, that implies a 12–13% domestic trajectory. Over time, India should rise from 53% to 60% of total revenue.
Chopra: "In the past 3 years, we have managed to transition the India domestic business from operating in stable, less growth segments to now operating majorly in progressive segments."
International Business: A Tale of Two Strategies
- South Africa rationalization is the drag: The strategic decision to prune the South Africa portfolio suppressed reported international revenue to INR383 crore. Excluding South Africa, the international business posted modest growth. The rationalization will continue through Q1 FY25.
- Export branded generics performing well: While CDMO saw a minor dip from a high base and seasonal slowness, the branded generics export business was a bright spot.
- Russia is not next: Management explicitly stated there is no plan to rationalize any other part of the international business. Any further portfolio optimization will target product-margin mix improvement, not country exits.
- U.S. ambitions remain measured: The U.S. business is expected to grow from $30 mn to $50 mn in two to three years, with no direct representation planned. The strategy stays focused on 3–4 oral solid dosage filings per year, differentiated by a cosmetic release platform, not specialty or complex products.
Ophthalmology Entry: Scale with Unanswered Margin Questions
- Instant market position: The Novartis agreements place J.B. among the top 4 players in the covered ophthalmology market. The acquired portfolio includes 5 brands holding the #1 position and 4 more in the top 3 in their respective molecule segments.
- Details withheld: Management declined to comment on the portfolio’s gross margin profile, the required other-expense or employee-cost investments, or the EBITDA margin outlook for FY25/26. They also deflected a question on near-term dry-eye product plans.
- 100-day review promised: A fuller briefing on the ophthalmology opportunity, including economics and strategy, is promised after the Q4 results, once management has completed its first 100 days with the business.
CDMO: Capacity Built, Growth Levers Identified
- Capacity expansion complete: Manufacturing and packaging capacity for 18 crore lozenges was executed as planned by end-December, up from the 13–14 crore throughput rate exiting Q2.
- Three growth levers: (1) New geographies: Europe, South Africa, Mexico, Brazil. (2) New partners, though management declined to name them. (3) New therapeutic segments: launches expected in lozenges, pain, sleep disorders, oral thrush, and immunity wellness starting in H2 FY24 and into FY25.
- Revenue ambition: CDMO is guided to reach close to $50 mn in the near term and $100 mn in three to five years. Its revenue share should rise from 12% today to 20% over time.
Margins: Current Comfort, Future Upside
- Gross margin leap: The 530 bps YoY gross margin expansion was driven by two levers: an increasing chronic mix within domestic business (Razel, Cilacar, Nicardia, Azmarda) and cost-improvement initiatives. Softening input rates from Q1 flowed through materially in Q3.
- EBITDA margin guidance held at 25–27%: Management expressed confidence in delivering this range, noting that if no external uncertainty or volatility arises, current margins should sustain without significant incremental investment in the existing domestic business.
- Upgrade path signaled: As the contribution from chronic therapies and CDMO becomes substantial, the margin guidance will be revised upward. The combined India-plus-CDMO revenue ambition is 80% of total revenue, up from 65% today.
- ESOP charge stabilized: A sequential increase in ESOP expense reflected fair-value adjustments. Going forward, the quarterly charge will remain at the current level with no further increases expected.
- Freight cost watch: Some freight cost impact will persist in Q4 based on November and December trends.
Khanna: "If there is no uncertainty and volatility, we should be maintaining the margins, which we currently have, right? Because we do not necessarily have to invest significantly in part of our existing domestic business."
Azmarda: Defending in a Tougher Market
- Market growth undershot expectations: The market grew 2x, not the anticipated 2.5x, while generic entry intensified competition. J.B. continues to protect market share and drive therapy adoption with cardiologists.
- Execution on track, with a small miss: On a month-on-month sequential basis, volumes could have been 8–10% higher based on initial estimates, but management characterized the trajectory as on the right path and not a cause for panic.
Khanna: "Yes, we have some higher expectations in terms of volumes increase and the price is -- the competition is much more intensified because of some of the generic entry, but that is not cause of panic because we continue to protect our market share."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| South Africa rationalization | Portfolio pruning to continue | Through Q1 FY25 |
| EBITDA margin | 25–27% (excluding ESOP) | Current / ongoing |
| Domestic revenue growth | 200–300 bps above IPM (~12–13%) | Ongoing |
| International formulations growth | Close to 10% | Ongoing |
| U.S. business scale | From $30 mn to $50 mn | Two to three years |
| CDMO business scale | Close to $50 mn near term; $100 mn longer term | Three to five years |
| U.S. filings run rate | 3–4 ANDA filings per year | Ongoing |
| Revenue mix ambition | India 60%, CDMO 20% (combined ~80%) | Over time |
| Top-line growth (next year) | 12–14% | FY25 |
| EBITDA growth (next year) | 16–18% | FY25 |
| Ophthalmology portfolio details | Full briefing on economics and strategy | Post Q4 FY24 results |
| Margin guidance revision | Upward revision when chronic and CDMO contributions become substantial | Undated |
Key Metrics
| Metric | Q3 FY24 |
|---|---|
| Revenue | ₹845 cr, up 7% YoY |
| Revenue growth excluding South Africa | 10% in Q3 FY24, 14% in 9M FY24 |
| Domestic revenue | ₹462 cr, up 14% YoY |
| International revenue | ₹383 cr |
| Gross margin improvement | 530 bps YoY |
| Operating EBITDA margin | 27.8% |
| 9M FY24 revenue | ₹2,622 cr, up 10% YoY |
| 9M FY24 domestic revenue | ₹1,432 cr, up 14% YoY |
| 9M FY24 international formulation revenue | ₹802 cr, up 6% YoY |
| 9M FY24 operating EBITDA (ex-ESOP) | ₹729 cr, margin at 27.8% |
| IPM growth vs J.B. growth (IQVIA MAT Dec 2023) | J.B. growing at 16% vs 10% IPM growth, fastest in top 25 |
| Covered market (CVM) growth | 12%, J.B. domestic business within CVM growing at 16% |
| Sporlac franchise portfolio size (IQVIA MAT Dec 2023) | ₹121 cr |
| CDMO quarterly average revenue | ~₹100 cr per quarter |
| CDMO guidance | $50 mn to $100 mn in 3 to 5 years |
| South Africa business size | $30 mn this year, private:public mix now 60:40 |
| U.S. business size | ~$30 mn, 15 owned ANDAs, filing 4-5 per year |
| Ophthalmology portfolio size (IMS reported) | ₹200 cr business |
| Net cash balance | ₹136 cr net positive |
| 9M FY24 operating cash flow | ₹614 cr, 84% of YTD operating EBITDA |
| FY25 revenue growth guidance | 12% to 14% |
| FY25 EBITDA growth guidance | 16% to 18% |
| FY25 ESOP expense guidance | ₹45 cr to ₹48 cr full year |
| Domestic business growth target vs IPM | 200 to 300 bps above IPM growth |
| International formulation growth target | close to 10% |